Pediatric statin administration: Navigating a frontier with limited data

Research output: Contribution to journalReview article

Authors

External Institution(s)

  • Children's Mercy Hospitals and Clinics
  • University of Missouri at Kansas City

Details

Original languageEnglish (US)
Pages (from-to)380-403
Number of pages24
JournalJournal of Pediatric Pharmacology and Therapeutics
Volume21
Issue number5
StatusPublished - Sep 1 2016
Peer-reviewedYes

Abstract

Increasingly, children and adolescents with dyslipidemia qualify for pharmacologic intervention. As they are for adults, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) are the mainstay of pediatric dyslipidemia treatment when lifestyle modifications have failed. Despite the overall success of these drugs, the magnitude of variability in dose-exposure-response profiles contributes to adverse events and treatment failure. In children, the cause of treatment failures remains unclear. This review describes the updated guidelines for screening and management of pediatric dyslipidemia and statin disposition pathway to assist the provider in recognizing scenarios where alterations in dosage may be warranted to meet patients’ specific needs.

    Research areas

  • Atorvastatin, Dyslipidemia, Fluvastatin, Lovastatin, Pediatrics, Pharmacogenomics, Pharmacokinetics, Pravastatin, Rosuvastatin, Simvastatin, Statin

Citation formats

APA

Wagner, J., & Abdel-Rahman, S. M. (2016). Pediatric statin administration: Navigating a frontier with limited data. Journal of Pediatric Pharmacology and Therapeutics, 21(5), 380-403. https://doi.org/10.5863/1551-6776-21.5.380

Harvard

Wagner, J & Abdel-Rahman, SM 2016, 'Pediatric statin administration: Navigating a frontier with limited data', Journal of Pediatric Pharmacology and Therapeutics, vol. 21, no. 5, pp. 380-403. https://doi.org/10.5863/1551-6776-21.5.380